The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AVH | -71.74% | -98.59% | -57.32% | -98% |
| S&P | +16.49% | +84.25% | +12.99% | +651% |
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
No news articles found for Avita Medical.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $26.08M | -10.6% |
| Gross Profit | $21.21M | -13.1% |
| Gross Margin | 81.32% | -2.4% |
| Market Cap | $201.23M | -46.4% |
| Market Cap / Employee | $0.77M | 0.0% |
| Employees | 260 | 25.6% |
| Net Income | -$20.16M | 16.7% |
| EBITDA | -$13.12M | 34.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $23.27M | -13.4% |
| Accounts Receivable | $13.60M | -8.3% |
| Inventory | 10.9 | 21.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.51M | -94.7% |
| Short Term Debt | $64.05M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -70.88% | 0.8% |
| Return On Invested Capital | -62.64% | -27.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.03M | 41.6% |
| Operating Free Cash Flow | -$7.61M | 23.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 31.61 | 49.33 | -30.90 | -10.96 | -200.15% |
| Price to Sales | 5.71 | 3.25 | 1.74 | 2.38 | -44.84% |
| Price to Tangible Book Value | 33.21 | -207.20 | -14.10 | -7.76 | -169.32% |
| Enterprise Value to EBITDA | -38.94 | -21.45 | -14.84 | -22.88 | 16.98% |
| Return on Equity | -236.7% | -410.5% | -985.5% | -1995.1% | 1224.01% |
| Total Debt | $74.27M | $70.73M | $68.04M | $67.56M | 2.72% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
